Relevance of antithrombin prescriptions at Strasbourg University Hospitals
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
This project will see if giving antithrombin to adults in intensive care or during surgery at Strasbourg University Hospitals is being used appropriately and linked to effective anticoagulation with heparin.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07276074 on ClinicalTrials.gov |
What this trial studies
This is a retrospective observational review of adult patients who received antithrombin at Strasbourg University Hospitals between January 1, 2022 and December 31, 2023. Investigators will extract clinical records to describe why antithrombin was given (for example during ECMO, RRT, or cardiopulmonary bypass), dosing and timing, and available laboratory monitoring. The analysis will look for patterns suggesting inappropriate use or associations with inadequate anticoagulation where antithrombin may have a role. No experimental treatments or changes to care are involved and patients who objected to reuse of their data are excluded.
Who should consider this trial
Good fit: Adults (age 18 or older) who received at least one dose of antithrombin in an intensive care unit or operating room at Strasbourg University Hospitals during the specified 2022–2023 period are the focus of this review.
Not a fit: People under 18, patients who did not receive antithrombin, those treated outside Strasbourg University Hospitals or outside the 2022–2023 window, and anyone who opted out of data reuse will not be included and will not benefit directly from this analysis.
Why it matters
Potential benefit: If successful, the work could help optimize when and how antithrombin is given, reducing ineffective anticoagulation and improving patient safety during extracorporeal support or surgery.
How similar studies have performed: Other observational studies have documented antithrombin deficiency during extracorporeal therapies, but randomized trials of routine antithrombin replacement have not demonstrated consistent outcome benefits, so routine replacement remains somewhat unproven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult subject (≥18 years old) * Female and male * Having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023. Exclusion Criteria: * Subject (and/or their legal representative, if applicable) having expressed their opposition to the reuse of their data for scientific research purposes * Minor subject
Where this trial is running
Strasbourg
- Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Xavier DELABRANCHE, MD
- Email: xavier.delabranche@chru-strasbourg.fr
- Phone: 33 3 69 55 09 36
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.